Compare Honest Company Inc (HNST) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Mesoblast Limited — how do they compare? Honest Company Inc trades at $5 (market cap $533.20M), while Mesoblast Limited trades at $14.33 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 3.3× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Mesoblast Limited for 14 Days on average.
| HNST | MESO | |
|---|---|---|
Market Cap | $533.20M | $1.75B |
Volume | 1,990,155 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $20.96 |
52-Week Low | $2.10 | $13.19 |
Typical Hold Time | 39 Days | 14 Days |
Enterprise Value | $436.81M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $4.99, up 1.22% today, with a bearish technical signal despite recent positive earnings momentum. The company shows mixed fundamentals with revenue of $371.32M in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations with $0.04 EPS, and institutional interest is growing with BlackRock's $25.66M investment in August 2026.
The stock faces headwinds from persistent unprofitability and declining revenue projections for 2026, though strategic exits are improving margins. Analyst consensus is mixed with a $5.30 price target, suggesting limited upside. Key risks include execution on profitability and competitive pressures in personal care markets.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
